

Commissioner Kyriakides and Gilead Sciences Europe Ltd - BTO 6 July 2020 Video-call

Present: Commissioner Stella Kyriakides; **Cabinet Members:** Giorgos Rossides (Head of CAB), Annukka Ojala (Dep Head of CAB), [REDACTED]

DG SANTE: Sandra Gallina (DDGI), Andrzej Rys (Dir B), [REDACTED] C3), [REDACTED] (B5), [REDACTED] (01), [REDACTED] (02),

Gilead Sciences: [REDACTED] Regulatory Affairs)

This was a follow-up to the meeting on 2 June 2020.

Summary – The Commissioner noted the media reports of the US government purchasing the available supply of remdesivir and stressed the importance to have a supply available also for EU patients and globally. To facilitate the supply and distribution in the EU, the Commission is investigating mechanisms to arrange purchasing. Gilead explained that there was supply in the EU, some already distributed to the Member States and the rest in the EU base of the company. Gilead noted that until the new manufacturing production was available, supplies might be limited.

Details of the discussion

The **Commissioner** noted that there had been press reports of the US government purchasing the global supply of remdesivir. She underlined that the authorisation had been granted by the Commission very quickly, and that from the moment the authorisation is granted there is an expectation of citizens that the medicine will be available to them. The Commission is in contact with the Member States regarding a coordinated EU procurement procedure.

Gilead representatives explained that the research on remdesivir was continuing and new studies into the combination with other medicines had started.. However, Gilead reassured that based on their estimates there were sufficient supplies for the EU also from July-September. Gilead expect that by October they will be in a position to meet the needs of patients in the EU.

The sequential procurement process through (i) the Emergency Support Instrument and (ii) a Joint Procurement Agreement for the period October to December was outlined to the Gilead representatives. Gilead explained that, for efficiency, they are asking Member States to arrange their supply through the Joint Procurement process rather than individual negotiations, which they will not engage in. They would like the EC to facilitate ensuring an equitable supply to Member States.

Commissioner reiterated the importance of providing equitable access to all MS.

END

Author: [REDACTED]